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Unchecked accumulation of reactive oxygen species (ROS)
compromisesmaintenance of hematopoietic stem cells. Regula-
tion of ROS by the tumor suppressor protein ataxia telangiecta-
sia mutated (ATM) is critical for preserving the hematopoietic
stem cell pool. In this study we demonstrate that the Foxo3
member of the Forkhead Box O (FoxO) family of transcription
factors is essential for normal ATM expression. In addition, we
show that loss of Foxo3 leads to defects in hematopoietic stem
cells, and these defects result fromanoveraccumulation of ROS.
Foxo3 suppression of ROS in hematopoietic stem cells is medi-
ated partly by regulation of ATM expression. We identify ROS-
independent modulations of ATM and p16INK4a and ROS-
mediated activation of p53/p21CIP1/WAF1/Sdi1 tumor suppressor
pathways as major contributors to Foxo3-null hematopoietic
stem cells defects. Our studies demonstrate that Foxo3
represses ROS in part via regulation of ATM and that this
repression is required for maintenance of the hematopoietic
stem cell pool.
Reactive oxygen species (ROS)3 such as superoxide anions
and hydrogen peroxide are by-products of oxidative metabo-
lism and are involved inmany signaling processes (1). However,
excess accumulation of ROS resulting from defects in ROS
scavenging is believed to impact cellular aging and the senes-
cence process (1), whereas the ability to withstand oxidative
stress has been correlated with enhanced longevity in several
species (1). In agreement with deleterious effects of ROS,
abnormal ROS accumulation has been implicated in the patho-
genesis of various diseases, including bone marrow failure and
disorders with high susceptibilities to malignancies such as
ataxia telangiectasia, Fanconi anemia, aswell asmalignancies of
hematopoietic tissues (2–5).
Regulation of ROS by ATM is essential for hematopoietic
stem cell self-renewal, because loss of ATM leads to depletion
of the hematopoietic stem cell pool and bone marrow failure in
old mice in a ROS-dependent manner (2). ATM serine/threo-
nine protein kinase is a critical enzyme in the regulation of
stress response to DNA damage, specifically double strand
DNA break (6). Loss of function mutations in ATM is associ-
ated with ataxia telangiectasia that is an autosomal disorder
characterized by neuronal degeneration, immunodeficiencies,
genomic instability, predisposition to lymphomas and other
malignancies, and extreme sensitivity to ionizing radiation (7).
Although ROS are found accumulated in several cell types and
tissues of ataxia telangiectasic patients (8) and antioxidant
enzymes are either up-regulated or down-regulated in ATM
mutant cells, the mechanism of ATM regulation of ROS is not
clear (6, 9).
The forkhead homolog DAF-16 is a major mediator of
defense against oxidative stress in Caenorhabditis elegans (10).
FOXO1, FOXO3a, FOXO4, and FOXO6 are the human
homologs ofDAF-16 and belong to the forkhead FoxO family of
winged helix transcription factors. Although FOXO6 is pre-
dominantly expressed in the brain, FOXO1, FOXO3a, and
FOXO4 are ubiquitous. As with DAF-16 in C. elegans, FoxO
transcription factors are critical regulators of oxidative stress in
mammals (11, 12). In particular, activated FOXO3a up-regu-
lates ROS scavenging enzymes in cultured cells (13, 14) and is
required for optimum expression of these enzymes in primary
mouse erythroid cells (12). FOXO3a responds to cellular stress
(including but not limited to oxidative stress) by inducing cell
cycle arrest at G1-S and G2-M checkpoints, repair of damaged
DNA, and apoptosis via up-regulation of genes that control
these processes (reviewed in Ref. 15).
FoxO proteins are negatively regulated by the highly con-
served PI 3-kinase/AKT signaling pathway (15). In response to
* This work was supported by American Cancer Society Research Scholarship
RSG LIB-110480, Career Enhancement Award K18 HL76510-01, a Black
Family exploratory research award, and Mount Sinai School of Medicine
research funds (to S. G.). The costs of publication of this article were
defrayed in part by the payment of page charges. This article must there-
fore be hereby marked “advertisement” in accordance with 18 U.S.C. Sec-
tion 1734 solely to indicate this fact.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental “Experimental Procedures,” Fig. 1, and Table 1.
1 Present address: Dept. of Physiology, National University of Singapore, Sin-
gapore.
2 To whom correspondence should be addressed. Tel.: 212-659-8271; Fax:
212-803-6740; E-mail: Saghi.Ghaffari@mssm.edu.
3 The abbreviations used are: ROS, reactive oxygen species; ATM, ataxia tel-
angiectasia mutated; MEF, mouse embryonic fibroblast; WT, wild type;
IRES, internal ribosome entry site; FCS, fetal calf serum; LTC-IC, long term
culture-initiating cell; NAC, N-acetyl-L-cysteine; 5-FU, 5-fluorouracil; IL,
interleukin; BrdU, bromodeoxyuridine; QRT, quantitative real time; FACS,
fluorescence-activated cell sorter; GFP, green fluorescent protein; SOD,
superoxide dismutase; shRNA, short hairpin RNA; DAPI, 4,6-diamidino-2-
phenylindole; CDK, cyclin-dependent kinase; PI, phosphatidylinositol;
HSC, hematopoietic stem cell(s); LT-HSC, long term HSC; ST-HSC, short
term HSC; BM, bone marrow.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 37, pp. 25692–25705, September 12, 2008
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
25692 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283 • NUMBER 37 • SEPTEMBER 12, 2008
This is an Open Access article under the CC BY license.
factors such as hematopoietic cytokines (16–19) or oncogenic
stimuli such as BCR-ABL oncoprotein (19), the AKT family of
serine/threonine protein kinases phosphorylates nuclear FoxO
and mediates their translocation to the cytosol where FoxO is
unable to induce the expression of their transcriptional targets
(16).
In response to oxidative stress, phosphorylation of FoxO
mediated by mammalian sterile 20-like kinase-1 (MST1) (20)
and Ral/Jun N-terminal kinase-dependent pathway results in
FoxO nuclear translocation and activation (21). Identification
of FoxO at sites of chromosomal translocations in human
tumors, including acutemyeloid leukemias, suggested a role for
these factors in tumorigenesis.
Under certain conditions of stress, such as when food is
scarce, DAF-16 is activated to promote the dauer formation.
We found the characteristics of the dauer that is in “juvenile
form, resilient, long lived, and reproductively immature” (10),
to resemble inmany respects the “quiescent” state of stem cells.
Because quiescence is (a) a major characteristic of stem cells,
(b) reminiscent of dauer formation, and (c) protected from apo-
ptosis by antioxidant function of FoxO homolog DAF-16, we
postulated that the Foxo3 (the mouse homolog of FOXO3a)
transcription factor that is the most highly expressed FoxO in
the bone marrow (12) may protect mammalian stem cells from
oxidative stress.
Recently, conflicting data as to the function of Foxo3 in the
regulation of hematopoietic stem cell activity have been
reported (11, 22). Studies by Tothova et al. (11) found a loss of
hematopoietic stem cell activity only when all three Foxo1,
Foxo3, and Foxo4 were deleted in mice. These authors did not
find any hematopoietic stem cell abnormalities as a result of
loss of Foxo3 alone (11). Conversely,Miyamoto et al. (22) found
that Foxo3 is essential for the maintenance of hematopoietic
stem cell activity. However, at steady state, these authors did
not detect a significant defect of hematopoietic stem cell fre-
quency in young mice (22). Here we provide our data showing
that Foxo3 is essential for the regulation of hematopoietic stem
cell frequency and activity in young mice. We further demon-
strate the following: (a) Foxo3 is critical for the regulation of
oxidative stress in hematopoietic stem cells, and (b) Foxo3
modulation of oxidative stress mediates Foxo3 regulation of
hematopoietic stem cell activity. Our in vivo and ex vivo data
demonstrate that loss of Foxo3 results in ROS accumulation
that mediates activation of p53/p21CIP1/WAF1/Sdi1 and in alter-
ations of hematopoietic stem cell cycling, specifically exit from
quiescence and G2/M arrest.
Furthermore, we demonstrate that Foxo3 is required for the
expression of ATM gene that is an essential factor for hemato-
poietic stem cell self-renewal. Using genetic loss and gain of
function approaches by RNA interference and retroviral trans-
duction of primitive hematopoietic stem cells, we demonstrate
that ATM deficiency participates in perturbations of ROS reg-
ulation in Foxo3-null hematopoietic stem cells.
These novel findings establish Foxo3 as a physiological reg-
ulator of oxidative stress in hematopoietic stem cells, demon-
strate that Foxo3modulation of ATM regulates oxidative stress
in hematopoietic stem cells, and provide insight into themech-
anism of Foxo3 regulation of stem cell cycling.We discuss what
we believe is the source of discrepancies between our results
and previous reports (11, 22) and present our model of Foxo3
regulation of hematopoietic stem cells.
EXPERIMENTAL PROCEDURES
Mice—The generation and genotyping of mice were per-
formed as described previously (23). Briefly, heterozygotes
Foxo3/ mice (129FVB/n) were backcrossed to FVB/n (F3),
and progenies (that were Cre) were intercrossed with litter-
mates to generate the experimental cohort (23). Littermates
were used as controls in all experiments. Protocols were
approved by the Institutional Animal Care and Use Committee
of Mount Sinai School of Medicine.
Cells—Mononuclear cells from blood, spleen, and bonemar-
row were prepared using lympholyte M (Cederlane, Hornby,
Ontario, Canada). ATM/ and wild type (WT)mouse embry-
onic fibroblasts (MEFs) were cultured in Dulbecco’s modified
Eagle’smedium containing 10% heat-inactivated bovine serum.
Retroviral Constructs and Plasmids—The full-length human
ATM cDNA from pMAT1 (24) was inserted upstream of the
IRES in the XhoI site ofMSCV-IRES-GFP (MIG) vector to con-
struct MIG-ATM. MIG-Foxo3 was described previously (19),
to construct pL4-shRNA Foxo3, synthesized shRNA oligomers
targeting Foxo3were annealed and cloned into EcoRI/XhoI site
downstream of H1 RNA polymerase III promoter of pL4
(Invitrogen) vector.
Flow Cytometry and Hematopoietic Stem Cell Isolation—For
Lin Sca-1 c-kithigh (LSK) cells, total bone marrow cells were
preincubated with 5% rat serum, c-Kit-APC, and Sca-1-PE (BD
Biosciences) and biotinylated hematopoietic multilineage
monoclonal antibody mixture (StemCell Technologies) con-
taining CD5 (lymphocytes), CD11b (leukocytes), CD19 (B
cells), CD45R (lymphocytes), 7-4 (neurophils), Ly-6G-Gr-1
(granulocytes), TER119 (erythyroid cells) antibodies to remove
mature cells and incubated with PECyc7-streptavidin second-
ary antibody. In addition to LSK staining, total bone marrow
cells were stained with FITC-CD34 and PECyc5-Flk2 antibod-
ies (eBiosciences) to subfractionate the long term and short
term HSC (Lin Sca1 c-Kithigh CD34/low Flk2low and Lin
Sca1 c-Kithigh CD34 Flk2low), respectively. Cell sorting was
performed using Influx (Cytopeia, Inc.) equipped with Spigot
software version 53.8.
Measurement of Intracellular ROS—An aliquot of cells (5 
105) first stained for LSKwas used for ROSmeasurement. Cells
were resuspended in pre-warmed phosphate-buffered saline,
2% FCS and loaded with 5 M 5-(and 6-)-chloromethyl-2,7-
dichlorodihydrofluorescein diacetate (Molecular Probes) incu-
bated in the dark for 20 min at 37 °C, 5% CO2. The oxidative
conversion of 5-(and 6-)-chloromethyl-2,7-dichlorodihy-
drofluorescein diacetate to its fluorescent product is measured
immediately by flow cytometry. In these experiments, bone
marrow cells incubated with H2O2 (500 M) were used as pos-
itive controls.
Long Term Culture-initiating Cell (LTC-IC) Assay—Long
term cultures were initiated with bone marrow cells (1  105)
cocultured on preestablished S17 stromal feeders inMyeloCult
M5300 (StemCell Technologies) containing freshly added
hydrocortisone (106 M) and carried as described previously
Foxo3 Regulates ATM and ROS in Hematopoietic Stem Cells
SEPTEMBER 12, 2008 • VOLUME 283 • NUMBER 37 JOURNAL OF BIOLOGICAL CHEMISTRY 25693
(25).N-Acetyl-L-cysteine (NAC) (100 M) was added weekly in
specified experiments.
Long Term Repopulation Assay—In these experiments
Foxo3/ (CD45.1, H2-Kq) mice backcrossed onto C57BL6
(CD45.1, H2-Kb purchased from NCI, National Institutes of
Health) (N5) were used. Wild type littermates were used as
controls. Lethally irradiated (12 gray as a split dose) congenic
C57BL6-CD45.2 mice (Charles River Laboratory) were recon-
stituted with intravenous injections of donor total bone mar-
row cells from8- to 10-week-oldwild type control (CD45.1, 2
105 cells) or Foxo3/ (also CD45.1, 1  106 cells) and 2  105
competitor bone marrow cells (CD45.2). Reconstitution of
donor-derived cells were distinguished from host cells by the
expression of CD45.1 versusCD45.2 antigens (BDBiosciences).
For the experiment in Fig. 2e, Foxo3/ (CD45.1) mice back-
crossed onto C56BL6 (CD45.1, F10) were used. FACS-sorted
100 Lin c-kitihigh Sca-1 CD34 bonemarrow cells fromwild
type and Foxo3/ mixed with 2  105 total bone marrow of
congenic C57BL6–CD45.2 were injected into lethally irradi-
ated (12 gray as a split dose) congenic C57BL6–CD45.2.
N-Acetyl-L-Cysteine Treatment—Mice were injected intrap-
eritoneally with 100 mg/kg body weight (Sigma) in phosphate-
buffered saline solution, pH7.4, every day for the indicated time
period. For cultured cells, NAC (100 M) was used for the indi-
cated time.
Retroviral Production and Transduction of Bone Marrow
Mononuclear Cells—Retroviral supernatants were produced as
described previously (26). Bone marrow mononuclear cells
were isolated from WT and Foxo3/ (8–10 week-old) litter-
mates treated 4 days previously with 5-fluorouracil (5-FU) (150
mg/kg, Sigma) using lympholyte-M (Cedarlane). Cells were
prestimulated for 2 days in Iscove’s modified Dulbecco’s
medium containing 15% heat-inactivated FCS supplemented
with IL-6 (10 ng/ml), IL-3 (6 ng/ml), and stem cell factor (100
ng/ml) (PeproTech EC), after which cells were resuspended in
retroviral supernatants (multiplicity of infection of 10) for 2
consecutive days, as described previously (27), and plated on
retronectin-coated dishes in Iscove’s modified Dulbecco’s
medium, 15% FCS containing the same factors. Forty eight
hours after the initiation, live GFP-positive cells were FACS-
sorted and lysed, and total RNA was isolated for gene expres-
sion analysis.
Cell Cycle Analysis—Micewere injected intravenously with 2
mg of 5-bromo-2-deoxyuridine (BrdU). At 19 h post-injection,
bone marrow cells were collected, stained for LSK, fixed, and
stained with 7-amino-actinomycin D and anti-BrdU antibody
(Pharmingen) for analysis. The G0/G1 analysis was performed
as described (28), and FACS-sorted LSK populations were col-
lected in Hanks’ buffered salt solution medium containing 10%
FCS, 1 g/liter glucose, 20 mM Hepes, pH 7.2, 50 g/ml vera-
pamil. Cells were then washed; Hoechst 33342 (20 g/ml,
Invitrogen) was added, and cells were immediately incubated at
37 °C for 45 min after which pyronin Y (1 g/ml, Sigma) was
added. Cells were incubated for another 15 min at 37 °C,
washed in cold medium, and resuspended in medium contain-
ing 1 g/ml of propidium iodide. Samples were immediately
analyzed by flow cytometry (BD Biosciences LSRII).
RNA Isolation and Quantitative Real Time (QRT)-PCR—
RNAisolation andQRT-PCRwere conducted as described (12).
In brief, total RNAwas isolated using RNeasy mini kit (Qiagen)
according to the manufacturer’s instructions. First strand
cDNA was synthesized using SuperScript (Invitrogen), QRT-
PCRs were performed using SYBR Green JumpStartTM Taq
ReadyMix (Sigma) in duplicate (Light Cycler 2.0, Roche Diag-
nostics). Gene-specific primers span the intron-exon boundary
by Primer Express 2.0 (ABI). Relative quantification was
achieved by normalization against endogenous -actin. For
primer sequence, see supplemental Table 1. In NIH 3T3 and
MEF experiments, TRIzol (Invitrogen catalog number 15596-
026) was used for total RNA extraction.
Western Blot Analysis—Lineage-negative WT, Foxo3-defi-
cient bone marrow cells or cells transfected with pL-4 plasmid
encoding for shRNA targeting Foxo3 and harvested after 96 h
(time required for RNA interference effect to take place) were
lysed in Laemmli buffer (5 ml of 4 Tris-HCl, pH 6.8, 4 ml of
glycerol, 0.8 g of SDS, 0.4 ml of -mercaptoethanol, 0.01 g of
bromphenol blue), resolved on 6.5% SDS-PAGE, and trans-
ferred to nitrocellulose membranes that were incubated with
the indicated antibodies as follows: 1) FOXO3a (Upstate Bio-
technology Inc., 07-702, 1:200); 2) ATM (GeneTex, GTX70103,
1:500), and 3) JAK2 (Upstate Biotechnology Inc., 06-255,
1:500). Band intensities were quantified by ImageQuant TL
software (Amersham Biosciences).
Immunofluoresence Staining—LSK cells were FACS-sorted
and cytospun onto glass slides fixedwith 4% paraformaldehyde.
After washing with phosphate-buffered saline, cells were per-
meabilized using 3% bovine serum albumin, 0.4% Triton X-100
and then incubated in 1% bovine serum albumin incubated
overnight with the following: 1) anti-FOXO1 (Santa Cruz Bio-
technology), 2) anti-FOXO3a (Upstate Biotechnology Inc.), 3)
active anti-caspase-3 (Promega), or 4) anti-FOXO4 (SantaCruz
Biotechnology) antibodies (1:250 dilution for each). Cells were
washed and stained with Alexa Fluor 594 anti-rabbit IgG anti-
body (1:400). For ATM-phosphoserine 1981 staining, LSK cells
were incubated with anti-ATM phosphoserine 1981 mouse
monoclonal antibody (Novus Biologicals) 1:500 dilution in 1%
goat serum.Cellswerewashed and stainedwithAlexa Fluor 594
anti-mouse IgG antibody (1:1000). Nuclei were stained with
Vectashield-DAPI (Vector Laboratories). Images were cap-
tured using Nikon EclipseE600microscope and processed with
Photoshop software. Data were quantified by Colocalizer Pro.2
software and Overlap coefficient according to Manders et al.
(50). ATM phosphorylation signal was quantified using Voloc-
ity software.
RESULTS
ROS-mediated Hematopoietic Stem Cell Deficiency in Foxo3-
null Mice—Foxo3 is the most highly expressed FoxO in the
bone marrow (12). Nuclear localization is often used as a sur-
rogate assay for FoxO activity. Hematopoietic stem cells are
highly limited in numbers, and only few cells can be obtained
from each mouse (average of 5000 cells from two mice). We
analyzed FoxO expression by both QRT-PCR and immuno-
staining in hematopoietic stem cells. Analysis of FoxO subcel-
lular localization showed that although both Foxo1 and Foxo3
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are expressed at similar levels in
hematopoietic stem cells (Fig. 1A),
Foxo3 is almost entirely nuclear
(over 95% nuclear as compared with
40% nuclear for Foxo1, see Fig. 1, B
and C) suggesting that Foxo3 is pre-
sumably highly active (and is the
most active FoxO) in hematopoietic
stem cells. Importantly, the expres-
sion of Foxo1 was not up-regulated,
and its subcellular localization was
only increased by 15% in Foxo3-null
hematopoietic stem cells (Fig. 1).
Foxo4 transcript or protein was
barely detectable in hematopoietic
stem cell compartment (Fig. 1).
These results suggest that Foxo3 is
the prevalent active FoxO in hema-
topoietic stem cells, and Foxo1 or
Foxo4 activity does not fully substi-
tute for loss of Foxo3.
Thus, to address the potential
evolutionary role of FoxO in the
regulation of quiescence of hemato-
poietic stem cells, we focused on
Foxo3 and investigated the hemato-
poietic stem cell compartment in
Foxo3/ mice. We found a signifi-
cant suppression of Foxo3-deficient
hematopoietic stem cell numbers
and activity (Fig. 1). In contrast to
Miyamoto et al. (22), we found that
the frequency (Fig. 2A) and the size
(Fig. 2B) of the Foxo3-null hemato-
poietic stem cell compartment was
significantly reduced as compared
with the wild type. The hematopoi-
etic compartment that is depleted
from mature cells (called lineage-
negative population) and expresses
cell surface markers Sca1 and high
levels of c-Kit receptor (Lin Sca1
c-Kithigh, LSK) encompasses all
stem cell activity, and this popula-
tion was substantially reduced in
young Foxo3-deficient mice as
comparedwithwild type littermates
(Fig. 2). Hematopoietic stem cell
(LSK) compartment is heterogene-
ous and consists of distinct popula-
tions of long term HSC (LT-HSC)
and short term (ST-HSC) repopu-
lating HSC (29). LT-HSC (Lin
Sca1 c-Kithigh CD34/low Flk2low)
have extensive self-renewing poten-
tial and give rise to ST-HSC (Lin
Sca1 c-Kithigh CD34 Flk2low)
with more restricted self-renewal
FIGURE 1. Foxo3 is the principal active FoxO in hematopoietic stem cells. A, QRT-PCR analysis of FoxO
expression in WT and Foxo3/ LSK cells. Relative quantification was achieved by normalization against
endogenous -actin. B, FoxO immunostaining of primitive hematopoietic stem (LSK) cells. Cells are FACS-
sorted and immunostained with anti-FOXO1, anti-FOXO3a, or anti-FOXO4 antibodies and counterstained with
DAPI. C, quantification of nuclear colocalization with DAPI as measured by Colocalizer Pro.2 software and
Overlap coefficient according to Manders et al. (50).
FIGURE 2. Foxo3/ HSC are functionally defective. A, flow cytometry analysis of live BM cells gated to
exclude doublets and mature cells as defined by their FSC and SSC characteristics. WT and Foxo3/ lineage
negative BM cells were analyzed for c-Kit versus Sca-1 expression (LSK) (contain all hematopoietic stem cell
activity). Frequency of LSK cells is noted. B, total numbers of LSK cells (p  0.02, n  15), LSK cells that are
CD34low Flk2low, enriched for LT-HSC (p  0.04, n  5) (48), and LSK cells that are CD34 Flk2low enriched for
ST-HSC (49) in WT and Foxo3/ mice. C, total numbers of LTC-IC-derived colonies were measured after 6
weeks in culture of WT (/) and Foxo3/ (/) mice (p  6.2  1010, n  30). D, % of CD45.1 peripheral
blood in lethally irradiated CD45.2 mice. Results shown are percentage of control. E, CD34 Lin c-kitihigh
Sca-1 (100 cells) from Foxo3/ (backcrossed to C56BL6, F10, CD45.1) or wild type C57BL6 (Cd45.1) mixed
with 2  105 total bone marrow (CD45.2) were transplanted into lethally irradiated recipients (CD45.2), and the
contribution to the peripheral blood formation of (CD45.1) cells was evaluated (n  5).
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potentials. Foxo3-deficient LT-HSC were the most highly
affected in the hematopoietic stem cell compartment (Fig. 2B,
p  0.02) suggesting that the self-renewing capacity of Foxo3-
null hematopoietic stem cell was compromised. This was fur-
ther supported by the suppression of Foxo3/ hematopoietic
stemcell functional activity. TheabilityofFoxo3-deficienthema-
topoietic stem cell in generating progenitors after 4 weeks in long
termculture (LTC-IC assay) in vitro (25)was notably decreased as
compared with their wild type counterparts (Fig. 2C, p  6.2 
1010, n 30). Similarly, the ability of Foxo3-deficient hemato-
poietic stem cells to repopulate in vivo lethally irradiated ani-
mals over several weeks was also severely compromised (Fig.
2D) suggesting that the suppression of stem cell activity was
intrinsic to Foxo3-null hematopoietic stem cells. We futher
evaluated the long term repopulating ability of Foxo3-null HSC
by using highly purified HSC from Foxo3/ mice backcrossed
to C57BL6 mice (F10) in our in vivo competitive repopulation
assay. We transplanted 100 CD34 Lin c-kitihigh Sca-1 that
are highly enriched in long term HSC from either wild type or
Foxo3/ (backcrossed to C56BL6, F10, CD45.1) along with 2
 105 total bone marrow (CD45.2) into lethally irradiated
recipients (CD45.2) and compared the contribution to periph-
eral blood formation of these cells with that of wild type
(CD45.1) cells. As shown in Fig. 2E, these experiments con-
firmed that Foxo3-null hematopoietic stem cells are highly
compromised in their long term abil-
ity to reconstitutemultilineblood for-
mation in lethally irradiated recipient
mice. Together these results strongly
indicate that Foxo3/ mice are
markedly deficient in their hemato-
poietic stem cell compartment (Fig.
2), specifically in cells with long term
repopulating ability (Fig. 2B).
Wenext askedwhether the defect
in Foxo3-null hematopoietic stem
cell compartment resulted from
abnormalities in scavenging ROS
(Fig. 3). Using a hydrogen peroxide-
sensitive probe, we found ROS to be
highly accumulated in Foxo3-defi-
cient populations of hematopoietic
cells containing all stem cells (LSK
cells) (Fig. 3, A and B). Increased
ROS concentrationswere specific to
Foxo3/ hematopoietic stem cells
(LSK), because accumulation of
ROS was similar in total WT and
Foxo3-deficient bone marrow cells
(Fig. 3B, compare top and bottom
panels).
In agreement with these results,
several antioxidant enzymes,
including catalase and mitochon-
drial superoxide dismutase 2
(SOD2, MnSOD), which are known
FoxO targets, and glutathione per-
oxidase 1 (GPX-1), which is not
known to be regulated by FoxO, were profoundly and specifi-
cally down-regulated in Foxo3-null LSK cells as analyzed by
QRT-PCR (Fig. 3C). These results suggest that Foxo3 is the
chief regulator of these antioxidant enzymes in hematopoietic
stem cells, and potential activity of Foxo1 and/or Foxo4 does
not fully complement loss of Foxo3 in hematopoietic stem cells.
Importantly, reducing ROS using NAC (100 M) that is a
generic ROS scavenger rescued the Foxo3-deficient hemato-
poietic stem cell phenotypes and the numbers of hematopoietic
stem cell-generated colonies over a 4-week period in culture
(LTC-IC assay, Fig. 3D). These findings demonstrate that
abnormal accumulation of ROS in Foxo3-null hematopoietic
stem cells leads to the defective activity of hematopoietic
stem cells. These combined findings strongly point to the del-
eterious impact of unchecked ROS as a result of loss of Foxo3
on inducing defective hematopoietic stem cell activity.
To evaluate whether loss of Foxo3 has any specific impact on
hematopoietic stem cell quiescence, G0 distribution ofWT and
Foxo3-deficient hematopoietic stem cells (LSK) was compared
usingmeasurements of RNA versusDNAcontents. These stud-
ies showed that loss of Foxo3 results in a significant reduction of
the proportion of bonemarrow hematopoietic stem cells (LSK)
inG0 that is concomitantwith the increased proportion of these
cells in S/G2/M suggesting that Foxo3 promotes hematopoietic
stem cell quiescence (Fig. 4, A and B). These results suggested
FIGURE 3. Defects in Foxo3-null hematopoietic stem cell activity are mediated by oxidative stress. A, flow
cytometry analysis of ROS concentrations in WT and Foxo3/ LSK cells (ROS overlay on unstained). B, quan-
tification of ROS measurements in WT and Foxo3/ total BM (top) and in LSK cells (bottom) from A. Results are
shown as mean  S.E. (p  0.0001, n  11). C, QRT-PCR analysis of antioxidant enzymes in RNA extracted from
freshly isolated live LSK cells. Results are shown as mean  S.E. of at least three cDNAs, each derived from
pooled LSKs from 2 to 3 WT and Foxo3/ mice. D, LTC-IC-derived colonies were measured in the presence and
absence of 100 M NAC added at each half-media change to long term cultures (p  0.0001, Student’s t test,
n  10). E, CFU-S-derived colonies were measured 12 days after injection of 105 WT or Foxo3-deficient bone
marrow cells into lethally irradiated hosts, in the presence or absence of NAC (100 M) injected intraperitone-
ally daily. One representative of two independent experiments is shown (n  5 in each group).
Foxo3 Regulates ATM and ROS in Hematopoietic Stem Cells
25696 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283 • NUMBER 37 • SEPTEMBER 12, 2008
that hematopoietic stem cells are in cycle and are producing
progenitors. However, despite these results, Foxo3-deficient
hematopoietic stem (LSK) cells cultured under optimum
growth factor conditions showed significantly reduced pro-
duction of total cells (Fig. 4C, upper panel) and progenitors
(Fig. 4C, lower panel). To further investigate this observa-
tion, the cell cycle distribution of the hematopoietic stem
cell compartment using the nucleotide analog BrdU uptake
in vivo was performed. As shown in Fig. 4E, loss of Foxo3 did
not significantly impact cell cycle distribution in the whole
bone marrow using BrdU uptake. In contrast, Foxo3 defi-
ciency resulted in an altered increase in G2/M phase and
decreased proliferation as measured by reduced incorpora-
tion of BrdU into the S phase of Foxo3-deficient hematopoi-
etic stem cells (LSK, Fig. 4, D and F). These results were in
sharp contrast to the observations reported by Miyamoto et
al. (22). In contrast to its impact on cell cycle distribution,
loss of Foxo3 did not appear to significantly alter the apopto-
tic rate of hematopoietic stem cells as measured by
annexin-V binding of freshly isolated LSK cells (data not
shown) or by the analysis of caspase 3 cleavage in FACS-
sorted LSK cells ex vivo (supplemental Fig. 1). Together
these studies suggest that loss of Foxo3 results in loss of
quiescence of hematopoietic stem cells that is concomitant
with alterations in the ability of hematopoietic stem cells to
complete their cycling.
ROS-mediated Activation of p53 Tumor Suppressor Path-
ways in Foxo3-deficient Hematopoietic Stem Cells—To obtain
insight into the Foxo3-null hematopoietic stem cell cycle alter-
ations, we analyzed transcript levels of candidate molecules
previously implicated in hematopoietic stem cell cycling and/or
known to be transcriptional targets of Foxo3. This analysis indi-
cated a significant reduction in expression of Foxo3 targets the
cyclin-dependent kinase (CDK) inhibitor 1B Cdkn1b (p27KIP1)
FIGURE 4. Decreased quiescence and impaired G2/M transition in Foxo3-deficient hematopoietic stem cells. A, FACS-sorted LSK cells are stained with
pyronin Y and Hoechst and analyzed by flow cytometry for G0/G1 distribution. Plot of percentage of wild type and Foxo3
/ LSK cells in G0 (negative for both
DNA-binding Hoechst and RNA-binding pyronin Y). B, mean  S.E. of experiments in A is shown (*, p  0.02, Student’s t test, pool of 2–3 WT and Foxo3/ mice
for each experiment, n  4). C, wild type and Foxo3/ 1000 LSK cells (in triplicate) were FACS-sorted and incubated in culture in the presence of steel factor
(100 ng/ml), IL-6 (10 ng/ml), IL-3 (10 ng/ml), and Flk2 (5 ng/ml), and cells (upper panel) and colony-forming cells (lower panel) generated after 5 days were
counted, and results are shown as mean  S.E. D, mice were injected with BrdUrd; after 19 h bone marrow (BM) was extracted, and FACS-sorted and -gated wild
type and Foxo3/ LSK cells (left panel) were analyzed for BrdUrd uptake (right panel). A representative cell cycle distribution is shown (n  8). E, as control, wild
type and Foxo3/ total bone marrow from D were analyzed for BrdUrd uptake (left panel), and a representative cell cycle distribution is shown (right panel).
F, graph of results from D shown as mean  S.E., *, p  0.002; **, p  3.06  108, n  8. 7-AAD, 7-amino-actinomycin D.
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transcript (17),Ccng2 (cyclinG2) (30), andCcnb1 (cyclinB) (31)
in Foxo3-null hematopoietic stem cells (LSK, Fig. 5A). Expres-
sion of p27KIP1 and cyclin G2, both important regulators of
hematopoietic stem cell cycling (28, 32), was profoundly down-
regulated in Foxo3-deficient hematopoietic stem (LSK) cells
(Fig. 5A). Similarly, Foxo3 transcriptional target cyclin B that is
required for completion of cell cycle and mitosis was signifi-
cantly reduced in Foxo3/ LSK cells (Fig. 5A). These results
strongly suggest that Foxo3 is a key transcriptional regulator of
p27KIP1, cyclin G2, and cyclin B in hematopoietic stem cells,
and potential functional Foxo1 (or Foxo4) does (do) not com-
plement for loss of Foxo3 in the regulation of these genes.
Unexpectedly, however, the expression of another Foxo3 tran-
scriptional target CDK inhibitorCdkn1a (p21CIP1/WAF1/Sdi1), with
critical functions in the repression of hematopoietic stem cell
cycling (33), was robustly up-regulated in Foxo3/ hemato-
poietic stem (LSK) cells (Fig. 5B). p21CIP1/WAF1/Sdi1 is an essen-
tial regulator of G1 andG2 checkpoints in response to oxidative
stress and DNA damage either as part of a transcriptional pro-
gram activated by p53 tumor suppressor or independently (34,
35). Up-regulation of p21CIP1/WAF1/Sdi1 was associated with a
significant up-regulation of p53 expression (Fig. 5B) suggesting
that enhanced expression of p21CIP1/WAF1/Sdi1wasmediated by
p53 activation in Foxo3-deficient hematopoietic stem cells. In
addition, known stress-response targets of activated p53, such
as theDNA repair gene growth arrest andDNAdamage-induc-
ible 45 (Gadd45a), also a transcriptional target of Foxo3, and
the antioxidant gene sestrin 2
(Sesn2), were significantly up-regu-
lated in Foxo3-deficient as com-
pared withWT hematopoietic stem
cells (Fig. 5B), further supporting
that p53 is activated as part of an
antioxidative stress response in
Foxo3-deficient hematopoietic stem
cells.
To evaluate the role of ROS in
alterations of Foxo3-deficient
hematopoietic stem cells (LSK), the
gene expression pattern of hemato-
poietic stem cells treated with a
ROS scavenger was examined.
Treatment with NAC for 5 days in
vivo followed by 2 days in vitro
resulted in a significant down-regu-
lation of both p21CIP1/WAF1/Sdi1 and
p53 expression in Foxo3-deficient
but not WT LSK cells (Fig. 5C), fur-
ther demonstrating that up-regula-
tion of p21CIP1/WAF1/Sdi1 transcrip-
tion in Foxo3-null hematopoietic
stem cells was mediated by an anti-
oxidant response of activated p53.
As anticipated, scavenging ROS in
Foxo3-null hematopoietic stem
cells did not rescue the expression
of direct targets of Foxo3 such as
cyclin G2 (Fig. 5C) or p27KIP1 (data
not shown) that were highly repressed in Foxo3-deficient
hematopoietic stem cells (Fig. 5A). These results confirmed
that cyclin G2 and p27KIP1 are direct targets of Foxo3, and their
expression is notmediated by ROS. Although the basal levels of
cyclin G2 (Fig. 5A) or p21CIP1/WAF1/Sdi1 (Fig. 5B) in wild type
LSKwere higher in ex vivo cultured cells as comparedwith levels
found in freshly isolated wild type LSK (Fig. 5B, likely because of
conditions in culture as comparedwith in vivo), thenotable reduc-
tion upon scavenging ROS was only seen with p21CIP1/WAF1/Sdi1
transcript but not with cyclin G2 and only in Foxo3-null and
not in wild type cells (Fig. 5C).
ATMLies Downstream of Foxo3—ATM is an essential regula-
tor of stress response and ROS-induced DNA damage that is
critical for hematopoietic stem cell self-renewal (2, 6). ATM
activates p53 via multiple pathways, including direct phospho-
rylation. To our surprise and in contrast to the observed up-
regulation of p53 expression, ATM transcript expression was
significantly and unexpectedly down-regulated in Foxo3-null
hematopoietic stem cells (Fig. 6A, 2-fold reduction, p 
0.0035). Importantly, this reduction in transcript expression
was associated with similar suppression of ATM protein
expression in primitive Foxo3-deficient hematopoietic cells
(Fig. 6B, over 2-fold reduction) suggesting that ATM lies down-
stream of Foxo3. The 2-fold reduction of ATM expression in
Foxo3-null primitive hematopoietic cells is of major signifi-
cance because ATM is required for genomic stability and
ATM/ mice exhibit an altered stress response phenotype
FIGURE 5. ROS-mediated and -independent alterations of tumor suppressor pathways in Foxo3/
hematopoietic stem cells. A, QRT-PCR analysis of some of cell cycle regulators that are direct target of FoxO in
wild type and Foxo3/ hematopoietic stem (LSK) cells. Results are shown as mean  S.E. of analysis of three
cDNAs each generated from a pool of two to three WT and Foxo3/ mice. B, QRT-PCR analysis of antioxidant
gene expression in wild type and Foxo3/ hematopoietic stem (LSK) cells. Results are shown as mean  S.E.
of analysis of three cDNAs each generated from a pool of two to three WT and Foxo3/ mice. C, wild type and
Foxo3/ mice were treated in vivo with or without NAC (100 mg/kg) every day for 5–7 days. BM LSK were then
isolated and incubated with NAC ex vivo for an additional 2 days after which total RNA was isolated for QRT-PCR
analysis. Results are shown as mean  S.E. of analysis of at least three cDNAs each generated from pool of two
to three wild type and Foxo3/ mice.
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(36) suggesting that loss of half of ATM may participate in the
defective Foxo3-null hematopoietic stem cell activity or stress
response. ATM-deficient hematopoietic stem cells in old mice
exhibit an up-regulation of both p16INK4a and p19ARF tumor
suppressors (2) that are generated from alternative open read-
ing frames of the INK4a locus. p16INK4a and p19ARF inhibit cell
cycle progression through inhibition of inhibitors (therefore
activation) of retinoblastoma and p53 proteins, respectively.
Although in Foxo3-deficient hematopoietic stem cells,
p16INK4a expression was significantly up-regulated, the expres-
sion of p19ARF remained unchanged (Fig. 6A).
In contrast to the expression of p53/p21CIP1/WAF1/Sdi1, the
levels of ATM or p16INK4a transcripts in Foxo3-null hemato-
poietic stem cells did not change significantly in response to the
NAC antioxidant treatment (Fig. 6C). These results further
confirmed that reduced ATM expressionmay be a direct result
of loss of Foxo3 and not ROS accumulation in primitive hema-
topoietic stem cells. In agreement with a functional ATM
downstream of Foxo3 in hematopoietic stem cells, the phos-
phorylation ofATMserine 1981 that is amarker ofATMkinase
activity (37) was slightly albeit significantly reduced at the
steady state in Foxo3-null hematopoietic stem cell-containing
population of LSK cells as compared with their wild type coun-
terparts (Fig. 6D).
NAC treatment led to a significant down-regulation of
p19ARF in Foxo3-deficient hematopoietic stem cells (LSK; Fig.
6C). This was highly unexpected because p19ARF transcript lev-
elswere similar inWTandFoxo3-null hematopoietic stemcells
(Fig. 6A). These findings suggest that ROS mediate regulation
of p19ARF expression in Foxo3-deficient but not in WT hema-
topoietic stem cells. Because p19ARF inhibits the degradation of
p53 protein through sequestration ofMDM2 (38), these results
suggest that ROS may induce activation of p53 antioxidant
function, both directly by stimulating the expression of p53
transcript and indirectly through up-regulation of p19ARF.
These combined findings suggest that ROS accumulation leads
to activation of p19ARF/p53 signaling pathway resulting in up-
regulation of p21CIP1/WAF1/Sdi1.
Foxo3 Is Required for Normal ATM Expression—We next
asked whether ATM expression is modulated by Foxo3 and
thus examined the expression ofATM inFoxo3-deficient prim-
itive hematopoietic cells expressing Foxo3 ectopically.WT and
FIGURE 6. ROS-independent repression of ATM in Foxo3-null primitive hematopoietic cells. A, QRT-PCR analysis of ATM, p16INK4a, and p19ARF in wild type
and Foxo3/ hematopoietic stem (LSK) cells. Results are shown as mean  S.E. of analysis of three cDNAs each generated from a pool of two to three WT and
Foxo3/ mice. B, Western blot analysis of ATM in lineage-negative bone marrow (BM) cells. JAK2 was used as a loading control. Band quantification (using
ImageQuant TL, right panel) normalized to 1 (for WT male) is shown below each lane. M, male; F, female. C, QRT-PCR analysis of same genes as in A after in vivo
NAC treatment as in Fig. 5C. Results are shown as mean  S.E. of analysis of at least three cDNAs each generated from pool of two to three wild type and
Foxo3/ mice. D, immunostaining of ATM-phospho-Ser-1981 in wild type and Foxo3-null LSK cells at the steady state (top) and quantification of phospho-
rylation signal in LSK cells by Volocity software (bottom); data are shown as mean  S.E. collected from n  20 cells.
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Foxo3-null bone marrow mononuclear cells highly enriched in
primitive hematopoietic cells as a result of a 4-day treatment
with a high dose of 5-FU (that ablate proliferating hematopoi-
etic cells (25, 39)) were isolated and transduced with the bicis-
tronic retroviral vector MSCV-IRES-GFP encoding for Foxo3
(Fig. 7A). Retroviral expression of Foxo3 and not the vector
control (Fig. 7B) resulted in a significant up-regulation of ATM
transcript in GFP-transduced Foxo3-null primitive hemato-
poietic cells suggesting that Foxo3 regulates ATM expression.
Expression of Foxo3 also induced significant down-regulation
of p53 and p16INK4a (Fig. 7B) without modifying the expression
of p19ARF (data not shown) in Foxo3/ primitive hematopoi-
etic cells.
As anticipated ectopic retroviral expression of Foxo3 and not
the vector control induced the expression of SOD2 and catalase
(Fig. 7C) in Foxo3-null primitive hematopoietic cells. In addi-
tion, overexpressed Foxo3 strongly and significantly induced
the expression of SOD1 (cytoplasmic SOD, CuZn-SOD) and
GPX-1 in primitive hematopoietic cells (Fig. 7C) suggesting
that expression of these antioxidant enzymes is also regulated
by Foxo3. Themechanism throughwhich Foxo3 induces SOD1
and GPX1 is not known.
To further examine Foxo3 regulation of ATM, we tested
ATM expression in NIH 3T3 cells overexpressing Foxo3 by
both QRT-PCR and Western blot. As in Foxo3-null primitive
hematopoietic cells, ectopic expression of Foxo3 and not the
vector control in NIH 3T3 cells resulted in a significantly
enhancedATMexpression asmeasured by bothQRTPCR (Fig.
8A) and Western blot (data not shown). Importantly, targeted
silencing of Foxo3 expression by RNA interference using two
distinct shRNAs resulted in significant reduction of expression
of both ATM transcript (Fig. 8B) and protein (Fig. 8C) in NIH
3T3 cells. A 50% reduction in Foxo3 expression resulted in over
25% reduced expression of ATM (Foxo3 shRNA3), whereas
80% reduction of Foxo3 resulted in 36% suppression of ATM
protein (Foxo3 shRNA4). However, because less than 100%
transfection efficiency may underestimate these results, we
repeated these experiments and FACS-sorted GFP (all
expressing shRNA targeting Foxo3) NIH 3T3 cells for analysis
(Fig. 8D). These experiments further confirmed our previous
findings and showed that over 95% reduction in Foxo3 expres-
sion leads to 70% reduction in ATM transcript expression fur-
ther demonstrating that Foxo3 is required for ATM expression
(Fig. 8D).
FIGURE 7. Ectopic expression of Foxo3 rescues expression of ATM and antioxidant genes in Foxo3-null primitive hematopoietic cells. A, Western blot
analysis of retrovirally produced Foxo3 in transduced NIH 3T3 cells. Cells (4  105) were transduced with 1⁄2 dilution of retroviral supernatant in the presence
of Polybrene (4 g/ml), and protein lysates were prepared 48 h later. Band quantification (using ImageQuant TL) normalized to 1 (for mock transduction) is
shown below each lane. Bar graphs of relative protein expression values are shown (below each Western blot). B, 5-FU-treated BM mononuclear cells were
transduced with the bicistronic MSCV-IRES-GFP encoding for Foxo3 (MIG-Foxo3). QRT-PCR analysis of gene expression in FACS-sorted GFP cells is shown. UNT,
untransduced. C, QRT-PCR analysis of antioxidant enzyme gene expression in cells from B. Results shown as mean  S.E. of analysis of three cDNAs each
generated from transduced cells of pool of four to five 5-FU-treated WT and Foxo3/ mice.
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Foxo3 and ATM Regulate the Expression of Antioxidant
Enzymes Independently—Although some ATM-null cells and
tissues, including ATM/ hematopoietic stem cells (2), accu-
mulate ROS, depending on tissues and cells, antioxidant
enzymes are up- or down-regulated in ATM-null cells, and the
exact mechanism of ATM regulation of ROS is unknown (6, 8,
9). Thus, we examined whether relative loss of ATM contrib-
utes to the deficiency of antioxidant gene expression observed
in Foxo3-null primitive hematopoietic cells (Fig. 3C). To this
end, retroviral supernatant highly expressing ATM was pre-
pared (Fig. 9A) and used to transduce Foxo3-null primitive
hematopoietic cells (Fig. 9B). Ectopic retroviral expression of
ATM and not the vector control corrected the transcript level
of p16INK4a, without much impact on p19ARF or p53 transcript
expression in Foxo3-null primitive hematopoietic cells suggest-
ing that ATMmay regulate p16INK4a expression. These results
further suggest that up-regulation of p16INK4a expression is the
result of the relative loss of ATM expression in Foxo3-null
primitive hematopoietic cells. Interestingly, retroviral expres-
sion of ATM restored the expression of antioxidant enzymes in
GFP Foxo3-null primitive hematopoietic cells (Fig. 9C) sug-
gesting that ATM is sufficient for the expression of SOD1,
SOD2, catalase, and GPX1 in the absence of Foxo3.
We next asked whether ATM is required for Foxo3 regula-
tion of antioxidant enzymes. ATM-deficient or WTMEFs (40)
retrovirally expressing either empty vector or Foxo3 or ATM
were examined for gene expression of antioxidant enzymes. As
shown in Fig. 10, SOD2 was significantly down-regulated in
ATM-deficient MEFs suggesting that ATM is required for
SOD2 expression. Ectopic expression of either Foxo3 or ATM
induced marked up-regulation of SOD1, SOD2, and GPX-1 in
ATM-deficientMEFs suggesting that Foxo3 regulation of these
antioxidant enzymes does not require ATM expression (Fig.
10). Up-regulation of the expression of these enzymes by over-
expression of ATM suggests, however, that although ATM is
only required for normal expression of SOD2, ATM may also
participate in the regulation of expression of SOD1, catalase,
and GPX-1 antioxidant enzymes.
These combined findings demonstrate that Foxo3 is required
for the regulation of ATM expression. In addition, these find-
ings strongly suggest that both ATM-mediated and independ-
ent pathways regulate oxidative stress in Foxo3-null primitive
hematopoietic stem cells.
DISCUSSION
Foxo3 Is a Physiological Regulator of Oxidative Stress in
Hematopoietic Stem Cells—Oxidative stress is broadly defined
as an imbalance between the production of oxygen radicals and
the ability to detoxify ROS to prevent oxygen radical-induced
injuries. Although the deleterious impact of ROS accumulation
on HSC has begun to be explored, little is known about the
FIGURE 8. Foxo3 is required for the regulation of ATM expression. A, QRT-PCR analysis of ATM gene expression in NIH 3T3 cells ectopically expressing
MIG-Foxo3 or MIG control (n  3). B, QRT-PCR analysis of ATM in NIH 3T3 cells transfected 72 h earlier with PL4-shRNA-Foxo3 (n  3) to silence Foxo3; shRNA3
and -4 are two distinct shRNAs targeting Foxo3. C, Western blot analysis of cells in B, and band quantification (using ImageQuant TL) normalized to 1 (for mock
transfection) is shown below each lane. D, 96 h after calcium phosphate transfection, GFP NIH 3T3 cells expressing shRNA targeting Foxo3 were FACS-sorted
and analyzed by QRT-PCR for Foxo3 and ATM expression.
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source of ROS and signaling pathways governing the regulation
of ROS in hematopoietic stem cells.
Our key finding is that Foxo3 is a physiological regulator of
oxidative stress that is essential for the regulation of hemato-
poietic stem cell fate. Foxo3 is required for the expression of
ATM and antioxidant enzymes. By regulating expression of
ATM tumor suppressor and antioxidant enzymes, Foxo3main-
tains ROS below a harmful threshold.
Foxo3 Is Essential for Normal ATM Expression—FoxO
functions parallel those associated with p53 tumor suppres-
sion, including induction of apoptosis, cell cycle arrest, and
antioxidative stress function. In addition, Foxo3 and p53
share a growing list of common targets such as Fas ligand,
PUMA, SOD2, Gadd45, and p21CIP1/WAF1/Sdi1 (as in our
studies) and undergo similar phosphorylation, acetylation,
and ubiquitination that regulate their activities, albeit in a
nonsimilar fashion (reviewed in Ref. 41). Cross-talk between
Foxo3 and p53 has also been observed in model culture sys-
tems (42, 43). Here we have shown that in Foxo3-null hema-
topoietic stem cells, p53 antioxidant response that is acti-
FIGURE 9. ATM rescues expression of antioxidant enzymes in Foxo3-null primitive hematopoietic cells. A, representative flow cytometry histo-
gram of GFP expression in 5-FU-treated bone marrow mononuclear cells transduced with the bicistronic MIG-ATM vector (left panel). Western blot
analysis of retrovirally produced ATM in transduced NIH 3T3 cells (right panel, top) and quantitative measurements of ATM protein expression are shown
as bar graph (right panel, bottom). Band quantification (using ImageQuant TL) normalized to 1 (for mock transduction) is shown below each lane.
B, QRT-PCR analysis of gene expression in FACS-sorted retrovirally transduced GFP-positive 5-FU-treated bone marrow mononuclear cells. Results
shown as mean  S.E. (as in Fig. 7). C, QRT-PCR analysis of antioxidant enzyme gene expression in cells from B, SOD, GPX-1. UNT, untransduced.
FIGURE 10. Foxo3 and ATM regulate independently expression of anti-
oxidant enzymes. A, wild type and ATM/ MEFs were transfected using
Lipofectamine with MIG-Foxo3 or MIG-ATM or empty MIG vector; GFP MEFs
were FACS-sorted 48 h later, and expression of antioxidant enzymes was ana-
lyzed by QRT-PCR. Results shown as mean  S.E. of two independent exper-
iments each performed in triplicate.
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vated and in contrast to the studies by Miyamoto et al. (22),
we observed a robust p53-mediated up-regulation of
p21CIP1/WAF1/Sdi1. Activation of p53/p21CIP1/WAF1/Sdi1 may
shield Foxo3-deficient hematopoietic stem cells from dam-
ages that may cause clonal expansion of this population.
Activation of p53 in response to oxidative stress in Foxo3-
null hematopoietic stem cells may suggest that p53 and
Foxo3 play complementary functions counterbalancing each
other as gatekeepers in hematopoietic stem cells.
ATM serine/threonine protein kinase is a critical enzyme in
the regulation of stress response to DNA damage. ATM activa-
tion enhances p53 activity through several pathways, including
direct phosphorylation of p53. ATM serine/threonine protein
kinase is activated in response to stress, especially stress-in-
duced by double strand DNA break that may also be ROS-in-
duced (6, 44). Activation of ATM involves its kinase domain
and is not known to affect its level of expression (6). Activated
ATM in turn results in accumulation and activation of p53
tumor suppressor.
Thus, down-regulation of ATM and ATM phosphoserine
1981 in Foxo3/ hematopoietic stem cells was not anticipated
(Fig. 6) and clearly is not mediated by ROS (Fig. 6C). The over
2-fold reduction of ATM expression in Foxo3-null hematopoi-
etic stem cells is of significance because ATM/ mice display
a compromised stress response (36). Our results demonstrate
that Foxo3 is essential for the regulation of ATM expression
(Figs. 6–8) as shown by the following: (a) ATM transcript and
protein are highly and specifically down-regulated in Foxo3-
null hematopoietic stem cells (Fig. 6); (b) ATM activity (ATM
phosphoserine 1981) is also down-regulated; (c) down-regula-
tion of ATMexpression in Foxo3-null hematopoietic stem cells
is ROS-independent; (d) overexpression of Foxo3 rescues the
expression of ATM in Foxo3-deficient primitive hematopoietic
cells (Fig. 7) and enhances ATM expression in NIH 3T3 cells
(Fig. 8A); and (e) shRNA silencing of Foxo3 in NIH 3T3 cells
results in significant down-regulation of ATM transcript and
protein (Fig. 8, B–D).
Furthermore, our results show that the relative ATM defi-
ciency participates in accumulation of ROS in Foxo3-null LSK
cells because of the following: (a) overexpression of ATM res-
cues expression of antioxidant enzymes in Foxo3-deficient
primitive hematopoietic cells (Fig. 9C) as does ectopic expres-
sion of Foxo3 in these cells (Fig. 7C); (b) ATM like Foxo3 is
required for full SOD2 expression (Fig. 10); and (c) ATM and
Foxo3 enhance the expression of several antioxidant genes
independently (Figs. 7, 9, and 10).
As inATM/ (2), p16INK4awas significantly up-regulated in
Foxo3-deficient hematopoietic stem cells (Fig. 6A). However,
in contrast to ATM/ hematopoietic stem cells (2), enhanced
expression of p16INK4a was not mediated by ROS (Fig. 6C).
This difference may be due to age-related regulation of ROS;
ROS-mediated up-regulation of p16INK4a was observed in
old (24-week-old) ATM/ hematopoietic stem cells,
whereas ROS-independent up-regulation of p16INK4a was
detected in young (8–12-week-old) Foxo3/ hematopoi-
etic stem cells in our studies (Fig. 6A). In Foxo3-deficient
hematopoietic stem cells, ROS alsomediated the pregulation
of p19ARF that inhibits the degradation of p53 (Fig. 6C).
These data suggest that in Foxo3-deficient hematopoietic
stem cells, multiple ROS-mediated signaling pathways lead
to the up-regulation and activation of p53.
Although ROS accumulationmediated the activation of p53/
p21CIP1/WAF1/Sdi1 in both Foxo3-null hematopoietic stem cells
(Fig. 6) and in a subset of erythroid precursor cells (12), its
impact on cell cycling of these populations was distinct. Loss of
Foxo3 led to relative loss of quiescence and a mitotic delay
(altered G2/M phase) in hematopoietic stem cells as compared
with a G1 arrest in erythroid precursor cells (that are about to
exit the cell cycle and differentiate) resulting in reduced eryth-
roid cell differentiation (12). These findings suggest that Foxo3
plays distinct functions in different cellular contexts (hemato-
poietic stem cell as comparedwith erythroid cell) andmay itself
be regulated differently in these cells.
We found that Foxo3-null LSK cells display a delay in the
G2/M phase of cell cycle (Fig. 4, D and F) consistent with the
notion that FOXO3a activity is required in G2/M for cell cycle
completion (31). These findings may result from loss of Foxo3
directly, from accumulation of ROS, or from reduced expres-
sion and/or activity of ATM in Foxo3-null LSK cells. Induced
nuclear localization of active FOXO3a fused to the ligand-bind-
ing domain of estrogen receptor in Rat-1 fibroblasts also
resulted in a delay in the G2/M phase of cell cycle (45) further
supporting that the function of FoxO may vary with cellular
context and conditions.
Foxo3 Is an Essential Regulator of Hematopoietic Stem Cell
Fate—We showed that Foxo3 is the principal active FoxO
(Foxo4 expression is barely detectable and Foxo1 is mostly
cytoplasmic and therefore presumably functionally mostly
repressed) in hematopoietic stem cells (Fig. 1). Our studies
determined that loss of Foxo3 alone results in severe reduc-
tion of expression of FoxO direct targets in hematopoietic
stem cells such as cell cycle and antioxidant enzyme genes
(Figs. 3C and 5), demonstrating the essential function of
Foxo3 in the regulation of these genes in hematopoietic stem
cells. In addition, we found substantial accumulation of ROS
in Foxo3-null hematopoietic stem cells (Fig. 3) similar to
what was observed in FoxO-null hematopoietic stem cells
(11). We further demonstrated that this ROS accumulation
mediates the loss of hematopoietic stem cell numbers and
function in young Foxo3-null animals (Fig. 3). Moreover, in
contrast to Tothova et al. (11) and as anticipated, we did not
find up-regulation of expression of direct targets of FoxO
such as p27KIP1 and cyclin G2 in response to NAC treatment
(Fig. 5).Whether the differences in gene regulation in response to
antioxidant treatment indicate distinct regulation of FoxO
direct targets in Foxo3-null as comparedwith FoxO-null hema-
topoietic stem cells require further investigation.
Together these findings strongly argue that Foxo3 (and not
other FoxO) is the principal regulator of oxidative stress and
cell cycle in hematopoietic stem cells. In addition, our studies
demonstrate that the function of Foxo3 in the modulation of
oxidative stress is essential for determining the fate of hemato-
poietic stem cells. These findings have significant conse-
quences beyond stem cells of hematopoietic origin as they sug-
gest potential important function for Foxo3 in other stem cell
systems such as oocytes, where loss of Foxo3 leads to their
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depletion (23), and likely Foxo3 regulation of oxidative stress in
nonhematopoietic stem cells.
The discrepancy between our study and studies reported
by Tothova et al. (11) may be due to the timing of experi-
ments relative to the excision of the knock-out alleles (4
weeks after excision) in the work of Tothova et al. (11).
Because we observe a clear phenotype only after 8–9 weeks
of age, we believe it may take this long for loss of Foxo3 (and
accumulation of ROS in Foxo3-null HSC) to make a delete-
rious impact on hematopoietic stem cell function. Analysis
of conditional Foxo3/ mice in the studies of Tothova et al.
(11) only 4 weeks after excision may not reveal the effect of
loss of Foxo3 in hematopoietic stem cells. However, differ-
ences in the mouse strain (mixed 129FVB versus mixed
129C57BL6) may explain some of the divergence in our
findings of Foxo3-null hematopoietic stem cell phenotype as
compared with Miyamoto et al. (22). In addition to the find-
ings byMiyamoto et al. (22), we found substantial ROS accu-
mulation in Foxo3-null hematopoietic stem cells (Fig. 3, A
and B) derived from youngmice.We demonstrated that ROS
mediates the repressed hematopoietic stem cell activity in
Foxo3-null mice (Fig. 3D). We further identified several
tumor suppressor pathways that are highly altered in Foxo3-
null hematopoietic stem cells via ROS-dependent and -inde-
pendent mechanisms and lead to G0 exit and G2/M arrest in
Foxo3-null hematopoietic stem cells (Figs. 5 and 6).
Foxo3-deficient hematopoietic stem cells exhibit a pheno-
type less pronounced but similar to hematopoietic stem cells
with deficiency in phosphatase and tensin homology that is a
negative regulator of PI 3-kinase/AKT (46, 47). Foxo3- and
FoxO-deficient hematopoietic stem cells display distinct cell
cycle and apoptosis phenotypes (Fig. 4) (11, 22). It is notewor-
thy that although we cannot rule out additional loss through
apoptosis, we did not detect significant apoptosis in freshly iso-
lated or short term cultured Foxo3-deficient hematopoietic
stem cells (supplemental Fig. 1). These combined findings indi-
cate that relative levels of ROS and FoxO activity have impor-
tant impacts on hematopoietic stem cell fate. Thus, tight regu-
lation of phosphatase and tensin homology/PI 3-kinase/Fox
signaling pathway is essential for preserving hematopoietic
stem cell pool and homeostasis.
Our studies suggest a model in which Foxo3 together with
ATM, p53, and p16INK4a provide a strong tumor suppressor
network in protecting stem cells from damage that may under-
mine their genomic stability and result in their clonal expansion
(model Fig. 11). Sustained activation of these pathways may
alternatively result in senescence leading to the defects seen in
Foxo3-null hematopoietic stem cells derived from aged mice
(22). Future elucidation of the mechanisms of regulation of
Foxo3 in hematopoietic stem cells, in particular potential inter-
actions of Foxo3 with coactivators and corepressors, as well as
identification of Foxo3 targets in stem cells, will be of funda-
mental importance for better understanding of aging of hema-
topoietic stem cells and malignant transformation in cancer
stem cells.
Note Added in Proof—While this manuscript was under review, a
new report showing that Foxo3 directly interacts with ATM and
regulates its activity in response to DNA damage was published (51).
These findings further the link between Foxo3 and ATM.
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